Published in PLoS Pathog on June 17, 2010
Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe (2011) 2.03
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio (2011) 1.76
A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol (2014) 1.69
The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev (2012) 1.45
Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot Cell (2011) 1.34
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides. PLoS Pathog (2011) 1.26
Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot Cell (2012) 1.24
The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. MBio (2012) 1.22
Toward an integrated model of capsule regulation in Cryptococcus neoformans. PLoS Pathog (2011) 1.21
Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. MBio (2013) 1.20
Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence. Eukaryot Cell (2011) 1.14
Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog (2011) 1.11
Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans. PLoS Pathog (2012) 1.11
Titan cell production enhances the virulence of Cryptococcus neoformans. Infect Immun (2012) 1.07
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe (2012) 1.07
The intracellular life of Cryptococcus neoformans. Annu Rev Pathol (2013) 1.06
Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics (2011) 1.06
Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol Rev (2011) 1.06
Polyploidy in fungi: evolution after whole-genome duplication. Proc Biol Sci (2012) 1.04
Ste50 adaptor protein governs sexual differentiation of Cryptococcus neoformans via the pheromone-response MAPK signaling pathway. Fungal Genet Biol (2010) 1.03
Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. PLoS Pathog (2011) 1.03
Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog (2015) 1.02
Titan cells in Cryptococcus neoformans: cells with a giant impact. Curr Opin Microbiol (2013) 1.02
Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. PLoS Pathog (2011) 1.02
Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides. PLoS Pathog (2013) 1.02
Competitive science: is competition ruining science? Infect Immun (2015) 1.01
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans. Front Microbiol (2011) 0.98
Molecular mechanisms of cryptococcal meningitis. Virulence (2012) 0.97
Systematic functional profiling of transcription factor networks in Cryptococcus neoformans. Nat Commun (2015) 0.96
The expanding implications of polyploidy. J Cell Biol (2015) 0.95
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. MBio (2013) 0.94
Cryptococcus neoformans: historical curiosity to modern pathogen. Yeast (2014) 0.94
Congenic strains of the filamentous form of Cryptococcus neoformans for studies of fungal morphogenesis and virulence. Infect Immun (2013) 0.94
Hydroxyurea treatment inhibits proliferation of Cryptococcus neoformans in mice. Front Microbiol (2012) 0.93
pH Response Pathways in Fungi: Adapting to Host-derived and Environmental Signals. Mycobiology (2011) 0.93
Comparative transcriptomics of the saprobic and parasitic growth phases in Coccidioides spp. PLoS One (2012) 0.92
Fungal pathogens-a sweet and sour treat for toll-like receptors. Front Cell Infect Microbiol (2012) 0.92
The cAMP/Protein Kinase A Pathway and Virulence in Cryptococcus neoformans. Mycobiology (2011) 0.91
The cryptic sexual strategies of human fungal pathogens. Nat Rev Microbiol (2014) 0.91
Morphogenesis in fungal pathogenicity: shape, size, and surface. PLoS Pathog (2012) 0.91
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Difficulty diagnosing chronic cryptococcal meningitis in idiopathic CD4+ lymphocytopenia. Neurol Sci (2011) 0.89
Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosity. Cold Spring Harb Perspect Med (2014) 0.87
Polyploid Titan Cells Produce Haploid and Aneuploid Progeny To Promote Stress Adaptation. MBio (2015) 0.87
Galleria mellonella model identifies highly virulent strains among all major molecular types of Cryptococcus gattii. PLoS One (2014) 0.87
Shift and adapt: the costs and benefits of karyotype variations. Curr Opin Microbiol (2015) 0.86
Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. MBio (2013) 0.85
Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol (2015) 0.85
Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect Immun (2013) 0.85
The Cryptococcus neoformans alkaline response pathway: identification of a novel rim pathway activator. PLoS Genet (2015) 0.85
The production of monokaryotic hyphae by Cryptococcus neoformans can be induced by high temperature arrest of the cell cycle and is independent of same-sex mating. PLoS Pathog (2013) 0.85
Stress signaling pathways for the pathogenicity of Cryptococcus. Eukaryot Cell (2013) 0.83
Morphology and its underlying genetic regulation impact the interaction between Cryptococcus neoformans and its hosts. Med Mycol (2015) 0.83
Pseudohyphal growth of Cryptococcus neoformans is a reversible dimorphic transition in response to ammonium that requires Amt1 and Amt2 ammonium permeases. Eukaryot Cell (2012) 0.83
Protein kinase A and fungal virulence: a sinister side to a conserved nutrient sensing pathway. Virulence (2012) 0.83
The battle with the host over microbial size. Curr Opin Microbiol (2013) 0.82
Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. MBio (2015) 0.82
A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans. Eukaryot Cell (2011) 0.82
Human fungal pathogens of mucorales and entomophthorales. Cold Spring Harb Perspect Med (2014) 0.82
Staying in Shape: the Impact of Cell Shape on Bacterial Survival in Diverse Environments. Microbiol Mol Biol Rev (2016) 0.82
Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence (2015) 0.82
Sexual reproduction of human fungal pathogens. Cold Spring Harb Perspect Med (2014) 0.82
The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med (2014) 0.81
Microrheology with optical tweezers: measuring the relative viscosity of solutions 'at a glance'. Sci Rep (2015) 0.81
Capsule growth in Cryptococcus neoformans is coordinated with cell cycle progression. MBio (2014) 0.81
Virulence mechanisms and Cryptococcus neoformans pathogenesis. Fungal Genet Biol (2014) 0.80
Ras1 acts through duplicated Cdc42 and Rac proteins to regulate morphogenesis and pathogenesis in the human fungal pathogen Cryptococcus neoformans. PLoS Genet (2013) 0.80
Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates. Front Microbiol (2016) 0.79
Cryptococcal phospholipase B1 is required for intracellular proliferation and control of titan cell morphology during macrophage infection. Infect Immun (2015) 0.79
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol (2016) 0.79
The cAMP/protein kinase A signaling pathway in pathogenic basidiomycete fungi: Connections with iron homeostasis. J Microbiol (2015) 0.78
Aimless mutants of Cryptococcus neoformans: failure to disseminate. Fungal Biol Rev (2012) 0.78
Cryptococcus neoformans: Tripping on Acid in the Phagolysosome. Front Microbiol (2016) 0.78
Ploidy dynamics and evolvability in fungi. Philos Trans R Soc Lond B Biol Sci (2016) 0.77
Clinicopathological features of pulmonary cryptococcosis with cryptococcal titan cells: a comparative analysis of 27 cases. Int J Clin Exp Pathol (2014) 0.77
Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans. Fungal Genet Biol (2014) 0.77
Large-Scale Chromosomal Changes and Associated Fitness Consequences in Pathogenic Fungi. Curr Fungal Infect Rep (2014) 0.77
Synergism Effect of the Essential Oil from Ocimum basilicum var. Maria Bonita and Its Major Components with Fluconazole and Its Influence on Ergosterol Biosynthesis. Evid Based Complement Alternat Med (2016) 0.77
The RGS protein Crg2 is required for establishment and progression of murine pulmonary cryptococcosis. Med Mycol (2010) 0.76
Cryptococcus neoformans hyperfilamentous strain is hypervirulent in a murine model of cryptococcal meningoencephalitis. PLoS One (2014) 0.76
Fungal morphogenesis. Cold Spring Harb Perspect Med (2014) 0.75
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools. Front Microbiol (2015) 0.75
Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions. Adv Appl Microbiol (2016) 0.75
Rim Pathway-Mediated Alterations in the Fungal Cell Wall Influence Immune Recognition and Inflammation. MBio (2017) 0.75
Physiological Differences in C. neoformans in vitro versus in vivo and Their Effects on Antifungal Susceptibility. Antimicrob Agents Chemother (2016) 0.75
Know your enemy: how to build and vanquish a global fungal scourge. Mycopathologia (2011) 0.75
Heterocycle thiazole compounds exhibit antifungal activity through increase in the production of reactive oxygen species in Cryptococcus neoformans/Cryptococcus gattii species complex. Antimicrob Agents Chemother (2017) 0.75
Genetic and epigenetic engines of diversity in pathogenic microbes. PLoS Pathog (2017) 0.75
Disarming Fungal Pathogens: Bacillus safensis Inhibits Virulence Factor Production and Biofilm Formation by Cryptococcus neoformans and Candida albicans. MBio (2017) 0.75
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia (1977) 4.83
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
The damage-response framework of microbial pathogenesis. Nat Rev Microbiol (2003) 4.07
The distinct morphogenic states of Candida albicans. Trends Microbiol (2004) 3.86
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
"Big it up": endoreduplication and cell-size control in plants. Curr Opin Plant Biol (2003) 3.13
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Expulsion of live pathogenic yeast by macrophages. Curr Biol (2006) 2.65
Morphogenesis in Candida albicans. Annu Rev Microbiol (2007) 2.39
Nuclear volume control by nucleoskeletal DNA, selection for cell volume and cell growth rate, and the solution of the DNA C-value paradox. J Cell Sci (1978) 2.38
Transcriptional control of dimorphism in Candida albicans. Curr Opin Microbiol (2001) 2.33
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Eukaryotic control on bacterial cell cycle and differentiation in the Rhizobium-legume symbiosis. Proc Natl Acad Sci U S A (2006) 2.29
Plant cell-size control: growing by ploidy? Curr Opin Plant Biol (2000) 2.22
Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell (2002) 2.21
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
Cryptococcus neoformans of unusual morphology. Appl Microbiol (1973) 1.67
Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol (2004) 1.66
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun (2006) 1.60
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect Immun (2007) 1.55
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence. Mol Microbiol (2007) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Melanisation of Cryptococcus neoformans in human brain tissue. Lancet (2000) 1.50
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Dimorphism in Histoplasma capsulatum: a model for the study of cell differentiation in pathogenic fungi. Microbiol Rev (1989) 1.41
Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol (2007) 1.40
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Soluble polysaccharides of Cryptococcus neoformans. Curr Top Med Mycol (1988) 1.29
Conversion of Blastomyces dermatitidis to the yeast form at 37 degrees C and 26 degrees C. J Clin Microbiol (1984) 1.28
Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog (2006) 1.27
Extreme polyploidy in a large bacterium. Proc Natl Acad Sci U S A (2008) 1.25
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am J Pathol (1996) 1.20
Large Cryptococcus neoformans isolated from brain abscess. J Clin Microbiol (1985) 1.19
Comparative analysis of Cryptococcus neoformans acid-resistant particles generated from pigmented cells grown in different laccase substrates. Fungal Genet Biol (2005) 1.05
Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Med Mycol (1999) 1.03
The volume and hydration of the Cryptococcus neoformans polysaccharide capsule. Fungal Genet Biol (2006) 1.01
Dimorphism in Histoplasma capsulatum and Blastomyces dermatitidis. Contrib Microbiol (2000) 0.98
Cell size control: new evidence for a general mechanism. Cell Cycle (2005) 0.96
The outcome of phagocytic cell division with infectious cargo depends on single phagosome formation. PLoS One (2008) 0.95
Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell Microbiol (2006) 0.95
Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit Rev Immunol (2007) 0.93
Biological and electron microscopic changes in gamma radiated Cryptococcus neoformans. Mycopathol Mycol Appl (1972) 0.93
Growth and pigment production on D-tryptophan medium by Cryptococcus gattii, Cryptococcus neoformans, and Candida albicans. J Clin Microbiol (2007) 0.89
Control of cell cycle and cell growth by molecular chaperones. Cell Cycle (2007) 0.83
Giant blastoconidia of Candida albicans. A case report and review of the literature. Arch Pathol Lab Med (2003) 0.81
Scanning electron microscope studies on the parasitic cycle of Coccidioides immitis. Mycopathologia (1985) 0.81
"Giant" blastoconidia of Candida albicans: morphologic presentation and concepts regarding their production. Diagn Microbiol Infect Dis (1999) 0.78
Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother (2005) 0.77
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev (2008) 3.52
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Retracted science and the retraction index. Infect Immun (2011) 3.35
Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis (2005) 3.14
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect (2012) 2.86
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 2.41
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Invest Dermatol (2009) 2.16
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother (2005) 1.92
Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol (2003) 1.90
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi--the Cryptococcus neoformans paradigm. Curr Opin Microbiol (2003) 1.79
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
DIAGNOSIS OF HISTOPLASMOSIS. Braz J Microbiol (2006) 1.67
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence (2011) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog (2008) 1.53
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Melanin and fungi. Curr Opin Infect Dis (2003) 1.48
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. Enferm Infecc Microbiol Clin (2011) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol (2011) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A (2008) 1.44
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2003) 1.40
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol (2007) 1.40
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40